Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients

Acta Clinica Croatica

Volumn 52, Issue 3, 2013, Pages 328-336

  Blaslov, Kristina ^a,b   Zibar, Karin ^a,b   Bulum, Tomislav ^a,b   Duvnjak, Lea ^a,b  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Diabetes mellitus, type 2; Exenatide; Glucagon like peptide 1; Vascular complications, diabetic

Indexed keywords

CREATININE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIET RESTRICTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; RISK FACTOR;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; RISK FACTORS; TREATMENT FAILURE; VENOMS;

EID: 84895792263     PISSN: 03539466     EISSN: 13339451     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. International Diabetes Federation. IDF Diabetes Atlas, 5th th edn. Brussels, Belgium: International Diabetes Federation, 2011. http://www.idf.org/diabetesatlas
2. L gminiene Z, Norkus A, Va lius L. Direct and indirect diabetes costs in the world. Medicina (Kaunas) 2004;40(1):16-26.
3. Cheunf BM, Ong KI, Cherny SS , Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-53.
4. DeFronzo RA. Lilly Lecture 1987. The triumvirate: betacell, muscle, liver. A collusion responsible for NIDDM . Diabetes 1988;37(6):667-87.
5. Armato J, DeFRON ZO RA, ABDUL -GHANI M, RUBY R. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta-cell dysfunction. Endocr Pract 2012;18(3):342-50.
6. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58(4):773-95.
7. Charbonnel B, Car iou B. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab 2011;13(2):99-117.
8. Chen YE , Dr uck er DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997;272(7):4108-15.
9. Holst JJ. The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes Obes Metab 2008;10 Suppl 3:14-21.
10. Gupta V. Pleiotropic effects of incretins. Indian J Endocrinol Metab 2012;16 Suppl 1:S47-56.
11. H olst JJ, Vilsboll T, Deac on CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297(1-2):127-36.
12. D eFr onzo RA, RATNE R RE, HAN J, KIM DD, FINEM AN MS, BARON AD. Effects of exenatide (exendin- 4) on glycemic control and weight over 30 weeks in metformin- treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-100.
13. Kendall DM , RIDDLE MC, ROSENSTO CK J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-91.
14. B use JB, HEN RY RR, HAN J, KIM DD, FINEM AN MS, BARON AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35.
15. Ma tthews DR, HOS KER JP, RUDENS KI AS, NAYLO R BA, TREACHE R DF, TU RNE R RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9.
16. Na than DM , BUSE JB, DAVIDSON MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203.
17. H eine RJ, van GAAL LF, JOHNS D, MIHM MJ, WIDEL MH, BRODO WS RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143(8):559- 69.
18. Pawa skar M, Li Q, Reynolds MW. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting. Curr Med Res Opin 2012;28(6):991-7.
19. Da vis SN , JOHNS D, MAGGS D, XU H, NO RTH RUP JH, BRODO WS RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007;30(11):2767-72.
20. Na uck MA, VARDALI I, DE ACON CF, HOLST JJ, MEIE R JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2010;54(1):10-8.
21. Anderson SL , TRUJILLO JM, McDE RMOTT M, SASEEN JJ. Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc 2012;52(4):466-71.
22. B uysschaert M, PREUMONT V, ORIOT PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab 2010;36(5):381-8.
23. Kirino Y, SATO Y, KAMIMOTO T, KAWAZOE K, MIN AKUCHI K, NAKAHO RI Y. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 2009;200(1):53-61.
24. Ma nnucc i E, PALA L, CIANI S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48(6):1168-72.
25. Lamers D, Fa mulla S, Wronkowitz N, et al.. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60(7):1917-25.